Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
If imminent results of Sanofi’s amcenestrant in Ameera-3 are positive Serds could finally see late-stage validation.
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
Alnylam has secured its first approval, but history suggests that launch will be far from easy.